Asana to Present First Clinical Data of ASN002, a Novel SYK/JAK Inhibitor, at American Society of Hematology Annual Meeting

Asana BioSciences, LLC today announced that preclinical and early clinical data from its ongoing Phase I/II trial of ASN002, the company’s potent oral inhibitor of spleen kinase (SYK) and the Janus kinase (JAK) family, will be presented at the 57th American Society of Hematology (ASH) annual meeting and exposition being held December 5 - 8 in Orlando, Florida. The presentation details are as follows:

ASN002 is a potent inhibitor of both SYK kinase and the JAK kinase family. SYK and JAK are tyrosine kinases involved in cytokine production and signaling. In preclinical studies ASN002 exhibited good oral bioavailability and demonstrated good safety margins. ASN002 demonstrated robust activity in a number of preclinical models of lymphoma and hematologic malignancies, including an ibrutinib-resistant lymphoma (DLBCL) cell line. ASN002 is currently under Phase I evaluation in a Phase I/II study in patients with solid tumors and lymphomas. The Phase II portion of the study will further evaluate safety, tolerability and efficacy in patients with diffuse large B-cell lymphoma, mantle cell lymphoma and follicular lymphoma. The study is ongoing, and dose escalation continues after assessment of the first two cohorts, which have shown good tolerability and safety. This will be the first clinical data presentation of ASN002, including safety, tolerability, preliminary efficacy and pharmacokinetics.

About Asana BioSciences, LLC

Asana BioSciences, LLC, an independent member of the Amneal alliance of companies, is a research and development company based in Bridgewater, New Jersey specializing in the discovery and development of new chemical and biological entities. Asana’s portfolio consists of multiple early-stage development candidates in a variety of therapeutic areas, including oncology, pain and inflammation, among others. Asana’s other lead molecule ASN001 (CYP17 inhibitor for prostate cancer) is currently in Phase I/II clinical studies in the US. Several other molecules in Asana’s portfolio are currently in the late stages of preclinical development. www.asanabiosciences.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20151130005874/en/